Minomic International Ltd

Minomic International Ltd, is a Sydney-based cancer diagnostics that has developed MiCheck® Prostate, an innovative blood test designed to assess the risk of clinically significant prostate cancer, marking a significant advancement in cancer diagnostics. Clinical studies have shown MiCheck® Prostate achieves a sensitivity of 95% with superior specificity surpassing existing testing methods. MiCheck® Prostate delivers enhanced reliability in early cancer detection by- reducing false positives by up to 50%, minimizing unnecessary biopsies and resulting in substantial healthcare cost savings- providing practitioners with better-quality information to support biopsy decisions. The test is commercially available in the USA through its high complexity CLIA testing lab in Maryland and in Australia via Sonic Healthcare’s pathology network. The company is in discussions re-launching the test in other territories.